Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Idenix Pharmaceuticals (NASDAQ: IDIX), a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C, exploded higher by as much as 235% after rival Merck (NYSE:MRK) agreed to buy the company for $3.85 billion.
So what: Under the terms of the deal, Merck will acquire Idenix for $24.50 per share in cash, a 239% premium to its closing value on Friday, in order to diversify its own hepatitis C development pipeline and hopefully catch a piece of the hepatitis C treatment market. According to Merck Research Laboratories President Roger Perimutter, Idenix's nucleoside/nucleotide chemistry and prodrug technologies should wind up complementing Merck's existing programs nicely. The board of directors of both companies have approved the deal with the transaction expected to close in the third quarter. Following the announcement research firm R.W. Baird upgraded Idenix to "outperform" from "neutral" -- a smooth move after its 230% run higher and all the more reason to ignore analyst ratings as largely unimportant to our investing thesis.
Now what: I don't say this lightly, but in my opinion, based on the data and facts we have in front of us right now, this might be one of the worst deals I've ever seen. Now understand that Idenix could deliver on samatasvir, its NS5A inhibitor, or its two other nucleotide prodrugs (IDX21437 and IDX21459), which would make this deal very much worth Merck's while. However, historically speaking, Idenix has one of the worst track records among all biotechs.
In 2010, Idenix had its then-lead compounds IDX184 and IDX320 placed on clinical hold by the Food and Drug Administration. Following this hold IDX184 continued on while IDX320 wound up be discontinued. In 2012, IDX184 was placed on clinical hold a second time along with IDX19368 following the death of a patient in Bristol-Myers Squibb's (NYSE:BMY) study involving BMS-986094 (the drug it acquired when it bought Inhibitex). Because Idenix's investigational drugs worked along the same pathway as Bristol's, the FDA decided to exercise caution. Long story short, both IDX184 and IDX19368 would be scrapped shortly thereafter. Finally, last year the FDA placed a clinical hold on IDX20963 until it delivered preclinical safety data to the regulatory agency. That's four clinical holds in four years folks (or five if you count IDX184 twice), aptly giving it the name of the "most unlucky biotech in the world" according to Foolish biotech specialist Brian Orelli.
The price paid for Idenix's inability to successfully get a drug into late-stage trials -- $3.85 billion -- is simply unfathomable, especially when you consider that Gilead Sciences already brought its blockbuster Sovaldi to market with sustained virologic response rates of 90% or better in most cases, and AbbVie's direct-acting antiviral, also capable of 90%-plus SVRs, is a likely candidate for approval perhaps before the end of this year. In a best-case scenario, Merck might bring a new therapy to market two years from now, but will there be any piece of the pie left to share by then? I'm not so sure.